|
Biological Activity:
Oral inhibitor of heat shorck protein 90 (Hsp90) under clinical development.
References:
B Böll et al. Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-κB and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell–Mediated Cytotoxicity. Clin. Cancer Res. 2009, 15(16), 5108–16. [online]
T Taldone et al. Targeting Hsp90: small-molecule inhibitors and their clinical development. Cur. Opin. Pharmacol. 2008, 8(4), 370-374. [online]
Chemical Name:
|